PURPOSE: Polymeric quick-dissolving films were developed as a solid dosage topical microbicide formulation for the vaginal delivery of the highly potent and non-toxic, dual-acting HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) pyrimidinedione, IQP-0528. METHODS: Formulated from approved excipients, a polyvinyl alcohol (PVA) based film was manufactured via solvent casting methods. The film formulations were evaluated based upon quantitative physicochemical evaluations defined by a Target Product Profile (TPP) RESULTS: Films dosed with 0.1% (w/w) of IQP-0528 disintegrated within 10 min with over 50% of drug released and near 100% total drug released after 30 min. The IQP-0528 films were found to be non-toxic in in vitro CEM-SS and PBMC cell-based assays and biologically active with sub-nanomolar efficacy against HIV-1 infection. In a 12 month stability protocol, the IQP-0528 films demonstrated no significant degradation at International Conference on Harmonization (ICH) recommended standard (25°C/65% relative humidity (R.H.)) and accelerated (40°C/75% R.H.) environmental conditions. CONCLUSIONS: Based on the above evaluations, a vaginal film formulation has been identified as a potential solid dosage form for the vaginal delivery of the topical microbicide candidate IQP-0528.
PURPOSE: Polymeric quick-dissolving films were developed as a solid dosage topical microbicide formulation for the vaginal delivery of the highly potent and non-toxic, dual-acting HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) pyrimidinedione, IQP-0528. METHODS: Formulated from approved excipients, a polyvinyl alcohol (PVA) based film was manufactured via solvent casting methods. The film formulations were evaluated based upon quantitative physicochemical evaluations defined by a Target Product Profile (TPP) RESULTS: Films dosed with 0.1% (w/w) of IQP-0528 disintegrated within 10 min with over 50% of drug released and near 100% total drug released after 30 min. The IQP-0528 films were found to be non-toxic in in vitro CEM-SS and PBMC cell-based assays and biologically active with sub-nanomolar efficacy against HIV-1 infection. In a 12 month stability protocol, the IQP-0528 films demonstrated no significant degradation at International Conference on Harmonization (ICH) recommended standard (25°C/65% relative humidity (R.H.)) and accelerated (40°C/75% R.H.) environmental conditions. CONCLUSIONS: Based on the above evaluations, a vaginal film formulation has been identified as a potential solid dosage form for the vaginal delivery of the topical microbicide candidate IQP-0528.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Alamelu Mahalingam; Adam P Simmons; Shweta R Ugaonkar; Karen M Watson; Charlene S Dezzutti; Lisa C Rohan; Robert W Buckheit; Patrick F Kiser Journal: Antimicrob Agents Chemother Date: 2011-01-18 Impact factor: 5.191
Authors: Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber Journal: Lancet Date: 2010-09-17 Impact factor: 79.321
Authors: Robert W Buckheit; Tracy L Hartman; Karen M Watson; Sun-Gan Chung; Eui-Hwan Cho Journal: Antimicrob Agents Chemother Date: 2007-10-29 Impact factor: 5.191
Authors: R W Buckheit; T L Kinjerski; V Fliakas-Boltz; J D Russell; T L Stup; L A Pallansch; W G Brouwer; D C Dao; W A Harrison; R J Schultz Journal: Antimicrob Agents Chemother Date: 1995-12 Impact factor: 5.191
Authors: Jonathan T Su; Ryan S Teller; Priya Srinivasan; Jining Zhang; Amy Martin; Samuel Sung; James M Smith; Patrick F Kiser Journal: Pharm Res Date: 2017-08-02 Impact factor: 4.200
Authors: Lindsay F Kramzer; Jessica Cohen; Jesse Schubert; Charlene S Dezzutti; Bernard J Moncla; David Friend; Lisa C Rohan Journal: Contraception Date: 2015-05-19 Impact factor: 3.375
Authors: Shweta R Ugaonkar; Justin T Clark; Lexie B English; Todd J Johnson; Karen W Buckheit; Robert J Bahde; Daniel H Appella; Robert W Buckheit; Patrick F Kiser Journal: J Pharm Sci Date: 2015-07-06 Impact factor: 3.534
Authors: K M Guthrie; L Rohan; R K Rosen; S E Vargas; J G Shaw; D Katz; E M Kojic; A S Ham; D Friend; K W Buckheit; R W Buckheit Journal: Pharm Dev Technol Date: 2017-06-21 Impact factor: 3.133
Authors: Kate M Guthrie; Rochelle K Rosen; Sara E Vargas; Melissa Guillen; Arielle L Steger; Melissa L Getz; Kelley A Smith; Jaime J Ramirez; Erna M Kojic Journal: Drug Deliv Transl Res Date: 2017-10 Impact factor: 4.617
Authors: Priya Srinivasan; Jining Zhang; Amy Martin; Kristin Kelley; Janet M McNicholl; Robert W Buckheit; James M Smith; Anthony S Ham Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191